Johnson & Johnson Invests $1B in PA, Creating 500 Jobs

Johnson & Johnson just announced plans to build a $1 billion cell therapy manufacturing facility in Lower Gwynedd Township, bringing 500 skilled jobs to Montgomery County and helping advance treatments that could save lives.

The global healthcare giant will transform a 154-acre property in Spring House into a cutting-edge plant that produces cell therapies. These treatments introduce specific cells into patients' bodies to fight diseases that were once considered untreatable.

The facility will open in 2031 and create more than 500 permanent biomanufacturing jobs when fully operational. During construction, the project will support over 4,000 additional jobs as crews develop the site.

Pennsylvania offered $41 million in tax credits, grants, and workforce training funds to bring the project home. The investment beat out competing states and marks a major victory for the commonwealth's economic development strategy.

Governor Josh Shapiro highlighted how far the state has come in attracting major employers. "Just a few years ago we weren't even on the field, but today we're competing and winning," he said from his Abington Township office.

The Ripple Effect

This announcement signals something bigger than one facility. Pennsylvania is quickly becoming a national leader in life sciences manufacturing, an industry that combines good-paying jobs with meaningful work that helps people.

The state created its first economic development plan in two decades, focusing on cutting red tape and making strategic investments in key industries. That approach is paying off as major companies choose Pennsylvania over other states.

Representative Madeleine Dean emphasized the facility's importance beyond economics. "Most importantly, this will bring life-saving medicine to people around the country," she said.

The Spring House site includes an existing 157,000 square foot building on land previously owned by Gwynedd Mercy University. Beacon Capital Partners purchased the property for $31.5 million in 2022.

Cell therapy represents the frontier of modern medicine, offering hope for conditions that traditional treatments struggle to address. Now, Pennsylvania workers will help manufacture these breakthrough therapies right in their own community.